In an unusual move, Stealth BioTherapeutics publicly disclosed an FDA rejection letter concerning its Barth syndrome treatment. The biotech is campaigning to garner regulatory reconsideration, highlighting the drug's life-saving potential for this ultra-rare disease. The FDA and company have struggled to agree on study data requirements, and the biotech warns of potential closure if the drug’s review is delayed, raising concern among patients and physicians.